Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month results;Traitement des néovaisseaux choroïdiens rétrofovéolaires naïfs du myope fort par injection intravitréenne de ranibizumab : résultats à 12 mois

Journal Francais d'Ophtalmologie

Volumn 33, Issue 5, 2010, Pages 327-333

  Cornut, P L ^a   Poli, M ^a   Feldman, A ^a   El Chehab, H ^b   Swalduz, B ^b   Burillon, C ^a   Denis, P ^a  

^a UNIVERSITÉ LYON 1   (France)

^b HIA Desgenettes   (France)

Author keywords

Antiangiogenic drugs; Choroidal neovascularization; Myopia; Ranibizumab

Indexed keywords

MONOCLONAL ANTIBODY; RANIBIZUMAB;

ADULT; AGED; CHOROIDAL NEOVASCULARIZATION; COMPLICATION; FEMALE; HUMAN; INJECTION; MALE; MIDDLE AGED; MYOPIA; PROSPECTIVE STUDY; TIME; VITREOUS BODY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; MYOPIA; PROSPECTIVE STUDIES; TIME FACTORS; VITREOUS BODY;

EID: 77953326471     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfo.2010.03.006     Document Type: Article

References (23)

1. Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol 53 (2008) 121-138
2. Cohen S.Y., Laroche A., Leguen Y., Soubrane G., and Coscas G.J. Etiology of choroidal neovascularization in young patients. Ophthalmology 103 (1996) 1241-1244
3. Yoshida T., Ohno-Matsui K., Yasuzumi K., Kojima A., Shimada N., Futagami S., et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 110 (2003) 1297-1305
4. Ohno-Matsui K., Yoshida T., Futagami S., Yasuzumi K., Shimada N., Kojima A., et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 87 (2003) 570-573
5. Chan W.M., Ohji M., Lai T.Y., Liu D.T., Tano Y., and Lam D.S. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol 89 (2005) 1522-1528
6. Hampton G.R., Kohen D., and Bird A.C. Visual prognosis of disciform degeneration in myopia. Ophthalmology 90 (1983) 923-926
7. Hotchkiss M.L., and Fine S.L. Pathologic myopia and choroidal neovascularization. Am J Ophthalmol 91 (1981) 177-183
8. Blinder K.J., Blumenkranz M.S., Bressler N.M., Bressler S.B., Donato G., Lewis H., et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report No. 3. Ophthalmology 110 (2003) 667-673
9. Ohno-Matsui K., Yoshida T., Uetama T., Mochizuki M., and Morita I. Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. Biochem Biophys Res Commun 303 (2003) 962-967
10. Tong J.P., Chan W.M., Liu D.T., Lai T.Y., Choy K.W., Pang C.P., et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141 (2006) 456-462
11. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
12. Ergun E., Heinzl H., and Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol 138 (2004) 434-438
13. Chan W.M., Lai T.Y., Wong A.L., Liu D.T., and Lam D.S. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 91 (2007) 174-179
14. Montero J.A., and Ruiz-Moreno J.M. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 91 (2007) 131-133
15. Ruiz-Moreno J.M., Montero J.A., Gomez-Ulla F., and Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 93 (2009) 448-451
16. Hernandez-Rojas M.L., Quiroz-Mercado H., Dalma-Weiszhausz J., Fromow-Guerra J., Amaya-Espinosa A., Solis-Vivanco A., et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 27 (2007) 707-712
17. Yamamoto I., Rogers A.H., Reichel E., Yates P.A., and Duker J.S. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91 (2007) 157-160
18. Sakaguchi H., Ikuno Y., Gomi F., Kamei M., Sawa M., Tsujikawa M., et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 91 (2007) 161-165
19. Mandal S., Venkatesh P., Sampangi R., and Garg S. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 17 (2007) 620-626
20. Chan W.M., Lai T.Y., Liu D.T., and Lam D.S. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: 6-month results of a prospective pilot study. Ophthalmology 114 (2007) 2190-2196
21. Silva R.M., Ruiz-Moreno J.M., Nascimento J., Carneiro A., Rosa P., Barbosa A., et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 28 8 (2008) 1117-1123
22. Lai T.Y., Chan W.M., Liu D.T., and Lam D.S. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 29 (2009) 750-756
23. Konstantinidis L., Mantel I., Pournaras J.A., Zografos L., and Ambresin A. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 247 (2009) 311-318